- Conditions
- Alzheimer's Disease Psychosis
- Interventions
- ACP-204, Placebo
- Drug
- Lead sponsor
- ACADIA Pharmaceuticals Inc.
- Industry
- Eligibility
- 55 Years to 95 Years
- Enrollment
- 1,074 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 53
- States / cities
- Chandler, Arizona • Scottsdale, Arizona • Anaheim, California + 36 more
Location Directory
Clinical trials in Houston, Texas
This page shows live ClinicalTrials.gov search results for Houston, Texas, with direct links to official study records plus on-page filtering and sorting for broad location searches.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
22526
Shown on this page
12
Current sort
Recently updated
Location scope
Houston, TX
Filters apply within this location only.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Showing 757–768 of 22,526 matching trials in Houston, TX.
Live ClinicalTrials.gov results.
Institutions in Houston
Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.
Live official records
Open in full search- Conditions
- Asthma
- Interventions
- Procedure: Investigational Procedures
- Other
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 6 Years and older
- Enrollment
- 2,500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 63
- States / cities
- Bessemer, Alabama • Chandler, Arizona • Mesa, Arizona + 49 more
- Conditions
- Advanced Cancer, Metastatic Cancer
- Interventions
- FS120
- Drug
- Lead sponsor
- invoX Pharma Limited
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 82 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 4
- States / cities
- New Haven, Connecticut • Houston, Texas • San Antonio, Texas + 1 more
- Conditions
- Metabolic Dysfunction-associated Steatohepatitis
- Interventions
- Efimosfermin alfa, Placebo
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 380 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2033
- U.S. locations
- 33
- States / cities
- Little Rock, Arkansas • Arcadia, California • Arroyo Grande, California + 27 more
- Conditions
- Obesity, Overweight and/or Obesity, Overweight
- Interventions
- PF-08653944, Placebo
- Drug · Other
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 954 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 35
- States / cities
- Canoga Park, California • Escondido, California • Modesto, California + 26 more
- Conditions
- Migraine
- Interventions
- K-645 100 mg, K-645 10 mg, Placebo
- Drug
- Lead sponsor
- TriGemX Bio, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 134 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025
- U.S. locations
- 18
- States / cities
- Oceanside, California • Atlanta, Georgia • Stockbridge, Georgia + 15 more
- Conditions
- Knee Cartilage Defects
- Interventions
- CARTISTEM® + Debridement, Debridement
- Biological · Procedure
- Lead sponsor
- Medipost, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 37
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Tempe, Arizona + 30 more
- Conditions
- Clear Cell Renal Cell Carcinoma, Cervical Carcinoma, Esophageal Carcinoma, Pancreatic Adenocarcinoma, Malignant Pleural Mesothelioma
- Interventions
- CTX131
- Biological
- Lead sponsor
- CRISPR Therapeutics AG
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 7
- States / cities
- Duarte, California • Chicago, Illinois • Boston, Massachusetts + 4 more
- Conditions
- Non-alcoholic Fatty Liver Disease
- Interventions
- Efimosfermin alfa
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 5
- States / cities
- Rialto, California • Miami Lakes, Florida • Tampa, Florida + 2 more
- Conditions
- Opioid Use Disorder
- Interventions
- Not listed
- Lead sponsor
- Indivior Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 480 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 35
- States / cities
- Costa Mesa, California • Escondido, California • Westport, Connecticut + 31 more
- Conditions
- Next Generation Sequencing (NGS), Surgical Site Infection (SSI), Fracture Fixation
- Interventions
- NGS diagnostic findings
- Diagnostic Test
- Lead sponsor
- Johns Hopkins Bloomberg School of Public Health
- Other
- Eligibility
- 18 Years to 84 Years
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2028
- U.S. locations
- 18
- States / cities
- Tuscaloosa, Alabama • Los Angeles, California • San Francisco, California + 15 more
- Conditions
- Advanced Malignant Neoplasm, Castleman Disease, Digestive System Carcinoma, Erdheim-Chester Disease, Lip and Oral Cavity Carcinoma, Lymphangioleiomyomatosis, Malignant Endocrine Neoplasm, Malignant Female Reproductive System Neoplasm, Malignant Male Reproductive System Neoplasm, Malignant Neoplasm, Malignant Respiratory Tract Neoplasm, Malignant Thoracic Neoplasm, Malignant Urinary System Neoplasm, Mesothelial Neoplasm, Metastatic Malignant Neoplasm, Metastatic Urothelial Carcinoma, Neurofibromatosis Type 2, Recurrent Adult Soft Tissue Sarcoma, Recurrent Breast Carcinoma, Recurrent Childhood Soft Tissue Sarcoma, Recurrent Digestive System Carcinoma, Recurrent Female Reproductive System Carcinoma, Recurrent Male Reproductive System Carcinoma, Recurrent Malignant Neoplasm, Recurrent Pharyngeal Carcinoma, Recurrent Thyroid Gland Carcinoma, Refractory Malignant Neoplasm, Soft Tissue Neoplasm, Stage III Breast Cancer AJCC v7, Stage III Pharyngeal Cancer, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7, Stage IV Pharyngeal Cancer, Stage IVA Pharyngeal Cancer, Stage IVB Pharyngeal Cancer, Stage IVC Pharyngeal Cancer, Thyroid Gland Neoplasm
- Interventions
- Bevacizumab, Cetuximab, Laboratory Biomarker Analysis, Pharmacological Study, Temsirolimus, Valproic Acid
- Biological · Other · Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 116 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2026
- U.S. locations
- 1
- States / cities
- Houston, Texas